Paydirt
JANX
Ticker

Janux Therapeutics, Inc.

JANX

JANX has 2 disclosed filings on Paydirt over the trailing twelve months from 2 corporate insiders: 0 purchases and 2 sales. Filers took a median of 1 day from execution to disclosure, and the most recent trade was executed Jan 2 and filed Jan 2. The most active filer was David Alan Campbell with 7 filings.

Add to watchlist
Filings, ttm
2
0 buys · 2 sells
Traders, ttm
2
2 insiders
Volume, ttmiDollar value disclosed in the window
$612K
estimated for Congress, as filed for insiders
Median delay
1d
execution to disclosure
Last traded
Jan 2
Filed Jan 2
ADViAverage daily dollar volume
–
not on file
Share price · 12M
$16.12 (-31.4%)
$34.74$23.46$12.18Sep 22 2025Mar 4Aug 14

Adjusted for splits and dividends.

Volume by month
$78.9M$39.4M$0Oct 2024Apr 2025Oct 2025Apr 2026Oct 2024 · buys $53.7MOct 2024 · sells $78.9MNov 2024 · sells $1.3MDec 2024 · sells $2.4MJan 2025 · sells $964KFeb 2025 · sells $102KMar 2025 · buys $25.3MApr 2025 · sells $100KOct 2025 · sells $501KJan 2026 · sells $111K
Buys $79.0M Sells $84.4M

Estimated for Congress, as filed for insiders · by filing month · past 24 months

Who filed
DC David Alan Campbell President and CEO 7 filings AM Andrew Hollman Meyer Chief Business Officer 5 filings AL Avalon BioVentures I, LP 10% owner 1 filing AP Avalon BioVentures SPV I, L.P. 10% owner 1 filing TD Thomas DiRaimondo Chief Scientific Officer 1 filing PK Peter Kolchinsky Director 1 filing JL Jay Lichter 10% owner 1 filing RL RA Capital Healthcare Fund LP Director 1 filing
Recent filings
David Alan CampbellSALE President and CEO $111K
8,072 sh × $13.73
Exec Jan 2
Filed Jan 2 · 5:30 PM ET Andrew Hollman MeyerSALE Chief Business Officer $501K
16,665 sh × $30.06
Exec Oct 28 2025
Filed Oct 30 2025 · 5:30 PM ET Andrew Hollman MeyerSALE Chief Business Officer $100K
3,334 sh × $30.00
Exec Apr 21 2025
Filed Apr 23 2025 · 5:30 PM ET RA Capital Healthcare Fund LPPURCHASE Director $25.3M
824,041 sh across 4 lots
Exec Mar 5 2025
Filed Mar 7 2025 · 5:30 PM ET Andrew Hollman MeyerSALE Chief Business Officer $102K
2,418 sh × $42.08
Exec Feb 3 2025
Filed Feb 5 2025 · 5:30 PM ET David Alan CampbellSALE President and CEO $300K
5,000 sh × $60.00
Exec Jan 7 2025
Filed Jan 8 2025 · 5:30 PM ET Andrew Hollman MeyerSALE Chief Business Officer $664K
12,134 sh across 3 lots
Exec Jan 2 2025
Filed Jan 3 2025 · 5:30 PM ET David Alan CampbellSALE President and CEO $1.4M
25,000 sh × $56.19
Exec Dec 24 2024
Filed Dec 27 2024 · 5:30 PM ET David Alan CampbellSALE President and CEO $1.0M
15,000 sh × $67.00
Exec Dec 3 2024
Filed Dec 3 2024 · 5:30 PM ET David Alan CampbellSALE President and CEO $1.3M
25,000 sh across 2 lots
Exec Nov 25 2024
Filed Nov 27 2024 · 5:30 PM ET David Alan CampbellSALE President and CEO $1.3M
25,000 sh across 2 lots
Exec Oct 28 2024
Filed Oct 30 2024 · 5:30 PM ET Jay LichterSALE 10% owner $178K
3,815 sh × $46.68
Exec Sep 13 2024
Filed Oct 24 2024 · 5:30 PM ET † Peter KolchinskyPURCHASE Director $53.7M
1,200,000 sh × $44.75
Exec Oct 18 2024
Filed Oct 22 2024 · 5:30 PM ET Avalon BioVentures SPV I, L.P.SALE 10% owner $77.4M
1,671,285 sh across 16 lots
Exec Oct 16 2024
Filed Oct 18 2024 · 5:30 PM ET Avalon BioVentures I, LPSALE 10% owner $14.2M
301,649 sh across 9 lots
Exec Sep 26 2024
Filed Sep 30 2024 · 5:30 PM ET David Alan CampbellSALE President and CEO $1.1M
24,205 sh across 2 lots
Exec Sep 27 2024
Filed Sep 27 2024 · 5:30 PM ET Thomas DiRaimondoSALE Chief Scientific Officer $200K
4,325 sh × $46.21
Exec Sep 27 2024
Filed Sep 27 2024 · 5:30 PM ET Andrew Hollman MeyerSALE Chief Business Officer $2.3M
50,000 sh × $45.96
Exec Sep 27 2024
Filed Sep 27 2024 · 5:30 PM ET Avalon BioVentures I, LPSALE 10% owner $21.2M
451,091 sh across 9 lots
Exec Sep 10 2024
Filed Sep 12 2024 · 5:30 PM ET Avalon BioVentures I, LPSALE 10% owner $10.1M
240,000 sh across 3 lots
Exec Sep 6 2024
Filed Sep 10 2024 · 5:30 PM ET